Last reviewed · How we verify
Double blind control period A140
A140 is a small molecule that targets the SGLT2 receptor.
A140 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | Double blind control period A140 |
|---|---|
| Also known as | KL-140 |
| Sponsor | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, A140 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly effective in treating type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of genital yeast infections
- Increased risk of urinary tract infections
- Dehydration
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: